他汀类药物是最广泛的可用药物治疗降低胆固醇水平，并控制其发展的处方药。所有的他汀类药物，如阿托伐他汀、氟伐他汀、洛伐他汀、匹伐他汀、普伐他汀、瑞舒伐他汀和辛伐他汀可用于心血管疾病事件的预防。众所周知，在治疗过程中一些服用他汀类药物的患者出现不良反应，如肝损害、癌症的风险和骨骼肌损害。因此，认识他汀类药物的安全性风险是很重要的。根据发表的他汀类药物的临床研究文献数据，分析和认识这类药物的安全性、不良反应及毒性的风险，并简要介绍了由美国心脏协会和美国心脏病学院基于4年评述而制定的2013年他汀类降胆固醇药物新使用指南。

Statins are the most widely prescribed drug available pharmacotherapy for the management of high blood cholesterol levels virtually since their development. All of statin-drugs, such as atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin used for prevention of cardiovascular disease event. As all know, some of the patients taking statins experience adverse effects during therapy. Such as liver toxicity, muscle injury and increased cancer risk are the top adverse effects. Therefore, it is important to understand the risks involved with the drug class and individual statins. This paper analyzes and understands the risks on safety, adverse effects and toxicity of statins from published the clinical research data in the literatures. And it also introduced to evaluate information of use and risks of statins and the "2013 Guidelines on Statins Drop Cholesterol Targets" based on a four-year review of the evidence formulated by the American Heart Association and the American College of Cardiology.

刘昌孝，中国工程院院士，从事新药研发、药物代谢动力学和新药评价研究工作。Tel：（022）23006863E-mail：liuchangxiao@163.com